E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Die Studie ist eine randomisierte, multizentrische, doppelt verblindete Studie zum Vergleich der Wirksamkeit und Verträglichkeit einer Behandlung mit Oleogel-S-10 über 3 Monate vs. Placebo bei Patienten mit gering- bis mittelgradigen aktinischen Keratosen des Kopfes inkl. des Gesichtes. Ziel der Studie ist es, die Wirksamkeit und die Tolerabilität dieser Behandlung zu prüfen. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Clinical clearance of all treated actinic keratoses |
|
E.2.2 | Secondary objectives of the trial |
• Histologically controlled complete clearance of the marker actinic keratosis • Histologically controlled downstaging of the grading of the marker actinic keratosis • 75 % clearance rate of the treated actinic keratoses • Dose response relationship for once and twice daily treatments • Time to clinically complete response • Tolerability as assessed by investigator and by the patient
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• At least two mild to moderate actinic keratoses located at the facial skin or the head (except lips) • histologically proven AK within three months before study entry. • prepared and able to give written informed consent • ≥ 18 years of age • prepared and comply with all study requirements, including the following: application of Oleogel-S10 on the treatment area once or twice a day 4 clinic visits during the pre-study, treatment, post-treatment, and follow-up period pre- and post-treatment biopsy for histological confirmation (of clearance) of AK-diagnosis • Representative histologic slide and tissue block were shipped
|
|
E.4 | Principal exclusion criteria |
• Active immunosuppressive therapy • data of clinically significant, unstable, cardiovascular or haematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or diseases Note: Patients with clinically stable medical conditions including, but not limited to, controlled hypertension, diabetes mellitus type II, hypercholesterolemia, or os-teoarthritis will be allowed to enter the study • known allergies to any excipient in the study drug • any dermatological disease and/or condition in the treatment or surrounding area (3 cm distances from treatment area) that may be exacerbated by treatment with Oleogel-S-10 or cause difficulty with examination • active chemical dependency or alcoholism, as assessed by the investigator • currently participating in another clinical study or have completed another clinical study with an investigational drug within the past 30 days • received topical treatment at the treatment area with diclofenac gel, imiquimod or 5-FU within a time period of 1 month • Invasive tumors within the treatment area, e.g.: merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma, the latter is accepted if completely surgically removed Note: A biopsy of any lesion within the treatment or surrounding area suggestive of malignancy should be performed at the pre-study screening visit. If invasive SCC or other malignant conditions are confirmed within the treatment area, the pa-tient will not be included in the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary end point is clinical clearance of all treated actinic keratoses |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |